

## Al Abbar Laboratories for Research and Medical Analysis مختبرات العبارللأبحاث و التحاليل الطبية



إدارة دبن للإعتماد طبقا لمواصفات الأيزو ١٥١٨٩ Dubai Accreditation Department for ISO 15189 المارة دبن للإعتماد طبقا لمواصفات الأيزو

## LABORATORY REPORT

Name : AMNEH YOUSEF File. No. : AAL02-381070

DOB/Gender

: 01-01-1996 (28 Yrs 2 Month 5 Days/Female)

: Self

Lab No.

: 22240660483

Referral Doctor

Referral Clinic

: Peshawar(Irham Medical Center)

Request Date : 06-03-2024 22:42:39

Clinic File No

: 42694

: NAS ADMINISTRATION SERVICES LTD Insurance

IMMUNOLOGY/SEROLOGY/INFECTIOUS DISEASES

Cutoff Index (COI)

**Test Name** Result Units Ref. Range Method 0.47 **Hepatitis B surface Ag ECLIA** 

Non Reactive: < 0.90

Borderline: >= 0.90 to < 1.0

Reactive: >= 1.0 Non-Reactive

Hepatitis B "s" Ag Interpretation Non-Reactive

Full HepB profile is recommended in case of a Reactive result. HBs Ag Index value is an instrument dependant value and should not be used for monitoring.

For monitoring HepB levels (track treatment), a quantitative viral load by PCR is advised.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 20/10/23

**Hepatitis B surface Ab(HBsAb)** IU/L Non-Reactive: < 10 **ECLIA** 

Reactive: >= 10

Conversion Formula: (Concentration in mIU/mL) x (1.0) = IU/L.

A "reactive" anti-HBs (or HBsAb) test result indicates that a person is protected against the hepatitis B virus.

This protection can be the result of receiving the hepatitis B vaccine or successfully recovering from a past hepatitis B infection

less than 10 IU/L- further vaccination recommended.

Please note Reference Range Reviewed w.ef 15/10/23

To evaluate vaccination efficacy- Assay for anti- HBS after two months of third dose.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. Remarks:

Test result to be interpreted in the light of clinical history and to be investigated further if necessary.

Sample Type: Serum

----- End Of Report ------

These tests are accredited under ISO 15189:2012 unless specified by (\*) Sample processed on the same day of receipt unless specified otherwise. Test results pertains only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

Dr. Solmaz Siddiqui Laboratory Director DHA/LS/248469

Patient Sample Collected On: 06-03-2024 20:00:00

Authenticated On: 06-03-2024 23:50:50 Released On: 07-03-2024 00:00:06

Received On: 06-03-2024 22:42:00

Esmeralda Obenita Lab Incharge

DHA/LS/2992011/ 241430

